These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 21385081)

  • 1. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
    Pasquali D; Santoro A; Bufo P; Conzo G; Deery WJ; Renzullo A; Accardo G; Sacco V; Bellastella A; Pannone G
    Thyroid; 2011 Apr; 21(4):391-9. PubMed ID: 21385081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
    Ulisse S; Baldini E; Sorrenti S; Barollo S; Prinzi N; Catania A; Nesca A; Gnessi L; Pelizzo MR; Mian C; De Vito C; Calvanese A; Palermo S; Persechino S; De Antoni E; D'Armiento M
    Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.
    Jo YS; Li S; Song JH; Kwon KH; Lee JC; Rha SY; Lee HJ; Sul JY; Kweon GR; Ro HK; Kim JM; Shong M
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3667-70. PubMed ID: 16772349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
    Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
    Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
    Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
    Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
    Xing M
    Endocr Rev; 2007 Dec; 28(7):742-62. PubMed ID: 17940185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Specific Long Non-Coding RNA Expression: Profile and Analysis of Association with Clinicopathologic Characteristics and BRAF Mutation in Papillary Thyroid Cancer.
    Wang Q; Yang H; Wu L; Yao J; Meng X; Jiang H; Xiao C; Wu F
    Thyroid; 2016 Dec; 26(12):1719-1732. PubMed ID: 27758138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
    Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
    Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
    Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
    Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
    Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
    Gandolfi G; Sancisi V; Torricelli F; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A
    J Clin Endocrinol Metab; 2013 May; 98(5):E934-42. PubMed ID: 23533235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The synergic effect of BRAF
    Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
    Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
    Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
    Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
    Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation.
    Holzer K; Drucker E; Oliver S; Winkler J; Eiteneuer E; Herpel E; Breuhahn K; Singer S
    Int J Oncol; 2016 Apr; 48(4):1679-87. PubMed ID: 26892809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.